Skip to main content
SpringerLink
Log in

Peroxisome Proliferator-Activated Receptor Gamma (PPARγ as a Novel Target for Prostate Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Peroxisome proliferator activatedreceptor-gamma (PPARγ) is a memberof the nuclear receptor superfamily ofligand-activated transcription factors. PPARγ is expressed at high levels inadipose tissue and plays a central role inadipocyte differentiation. Recent studieshave implicated PPARγ in thepathogenesis of several human malignancies.Here we review the evidence thatPPARγ contributes to prostatecarcinogenesis and the potential forPPARγ as a novel therapeutic targetfor prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83(5): 813–819, 1995

    Google Scholar 

  2. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83(5): 803–812, 1995

    Google Scholar 

  3. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Proc Natl Acad Sci USA 94: 4318–4323, 1997

    Google Scholar 

  4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953–12956, 1995

    Google Scholar 

  5. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284–287, 1998

    Google Scholar 

  6. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 18;241(2): 270–274, 1997

    Google Scholar 

  7. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O: Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPARgamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42(7): 892–895, 1999

    Google Scholar 

  8. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84(10): 3708–3712, 1999

    Google Scholar 

  9. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339(14): 953–959, 1998

    Google Scholar 

  10. Hamann A, Munzberg H, Buttron P, Busing B, Hinney A, Mayer H, Siegfried W, Hebebrand J, Greten H: Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur J Endocrinol. 141(1): 90–92, 1999

    Google Scholar 

  11. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet Mar 7(3): 435–440, 1998

    Google Scholar 

  12. Wang XL, Oosterhof J, Duarte N: Peroxisome proliferator-activated receptor gamma C161 - >T polymorphism and coronary artery disease. Cardiovasc Res 44(3): 588–594, 1999

    Google Scholar 

  13. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S: Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 260(1): 122–126, 1999

    Google Scholar 

  14. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405(6785): 421–424, 2000

    Google Scholar 

  15. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4(9): 1046–1052, 1998

    Google Scholar 

  16. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4(9): 1058–1061, 1998

    Google Scholar 

  17. Seed B. PPARgamma and colorectal carcinoma: conflicts in a nuclear family. Nat Med 9: 1004–1005, 1998

    Google Scholar 

  18. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289(5483): 1357–1360, 2000

    Google Scholar 

  19. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94(1): 237–241, 1997

    Google Scholar 

  20. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96(7): 3951–3956, 1999

    Google Scholar 

  21. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1(3): 465–470, 1998

    Google Scholar 

  22. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95(15): 8806–8811, 1998

    Google Scholar 

  23. Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60(6): 1604–1608, 2000

    Google Scholar 

  24. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97(20): 10990–10995, 2000

    Google Scholar 

  25. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58(15): 3344–3352, 1998

    Google Scholar 

  26. Butler R, Mitchell SH, Tindall DJ, Young CY: Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11(1): 49–61, 2000

    Google Scholar 

  27. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60(19): 5494–5498, 2000

    Google Scholar 

  28. Smith MR, Manola J, Oh W, Kaufman DS, Kantoff PW: Troglitazone treatment increases serum testosterone and sex hormone binding levels in men with prostate cancer. Submitted.

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital, Boston, MA, USA

    Matthew R. Smith

  2. Dana Farber Cancer Institute, Boston, MA, USA

    Philip W. Kantoff

Authors
  1. Matthew R. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip W. Kantoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, M.R., Kantoff, P.W. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ as a Novel Target for Prostate Cancer. Invest New Drugs 20, 195–200 (2002). https://doi.org/10.1023/A:1015670126203

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015670126203

Search

Navigation